Business
Update on Developmental and Clinical Activity
Update on Developmental and Clinical Activity.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 2269B ValiRx PLC 02 April 2013 \n\n \n \nFor release at 07:00 on 2 April 2013\n \nValiRx Plc\n(\"ValiRx\" or the \"Company\" or the \"Group\")\n \nUpdate on Developmental and Clinical Activity\n \nValiRx Plc (AIM: VAL), a life science company in clinical development with cancer diagnostics and anti-cancer therapeutics for personalised medicine, today provides an update on its recent activities. The Company will also be presenting at the prestigious American Association for Cancer Research Conference in Washington starting on April 6th 2013. The Conference is an annual event designed to showcase and bring together developments in all major areas of cancer research. There were nearly 17,000 participants in attendance last year. This is the first time ValiRx has been selected to give a presentation at the event, and the Company will be delivering two posters.\n \nThe Company has also been actively engaging with the scientific and investor community this winter, with a series of presentations at networking events in London, including One Nucleus on March 18th and the London Stock Exchange on 27th March. The Company has received positive feedback. In addition the Company has participated in scientific and industry events across the UK, Finland and Europe at which ValiRx has showcased its activities, and in particular in Oxford, London, Oulu and Turku in Finland, and in Barcelona and Brussels amongst other events in France and Denmark. \n \nSatu Vainikka, Chief Executive Officer of ValiRx, said: \"Our technical and commercial progress over the past year has been pleasing and we are well set for the future as we look to further establish ourselves at the forefront of personalised oncology development.\"\n \nA number of key milestones have been achieved, in particular for VAL 201, the Company's leading anti-cancer therapeutic which has been in the clinical development phase for prostate cancer since the summer of 2012. Preclinical development work for various other indications has continued with many interesting potential therapeutic findings and the development of far greater depth of understanding and scientific background of the compound. No significant toxicological effects have been detected in regulatory studies thus far. \n \nHaving been in dialogue with the reg...